844
Views
12
CrossRef citations to date
0
Altmetric
Research Article

Nostotrebin 6, a bis(cyclopentenedione) with cholinesterase inhibitory activity isolated from Nostoc sp. str. Lukešová 27/97

, , , , , & show all
Pages 414-420 | Received 19 May 2009, Accepted 28 Jul 2009, Published online: 16 Mar 2010
 

Abstract

Nostotrebin 6, a new polyphenolic compound with a fully substituted 2,2′-bis(cyclopent-4-en-1,3-dione) skeleton, was isolated from a methanolic extract of the cyanobacterial strain Nostoc sp. str. Lukešová 27/97. The structure of this compound was determined using X-ray crystallography and further supported by NMR, IR spectroscopy, and MS. Nostotrebin 6 is an S-parabolic I-parabolic noncompetitive inhibitor of acetylcholinesterase (IC50 = 5.5 μM) and an S-parabolic I-parabolic mixed inhibitor of butyrylcholinesterase (IC50 = 6.1–7.5 μM). The inhibitory potency of nostotrebin 6 was compared with that of tacrine and galanthamine.

Declaration of interest: This research was supported by Project ME 874 of the Ministry of Education, Youth, and Sports of the Czech Republic. The Czech Science Foundation further supported this work through Project 522/06/1090. Partial funding was also provided by Project MSM6007665808 of the Ministry of Education, Youth, and Sports of the Czech Republic, and also by Projects AVOZ 50200510 and AVOZ 6060521 of the Czech Academy of Sciences.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.